Showing 7011-7020 of 9381 results for "".
The Benefits of Balneotherapy for Atopic Dermatitis
https://practicaldermatology.com/programs/practical-dermatology-type-ii-inflammation-journal-club/the-benefits-of-balneotherapy-for-atopic-dermatitis/39776/Practical Dermatology editorial board member Peter Lio, MD, and Karan Lal, DO, MS, FAAD, discuss the use of balneotherapy as an adjunctive treatment for dermatologic diseases, including an International Journal of Biometeorology article titled, “Balneotherapy using thermal mineral water baths and deNoah Worcester 2024: Dr. Hinshaw on Onychomycosis
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-hinshaw-onychomycosis/24587/Molly Hinshaw, MD, FAAD, summarizes her lecture on diagnosis and management of onychomycosis at the 2024 Noah Worcester Dermatological Society meeting.CSF 2022 Highlights
https://practicaldermatology.com/conferences/cosmetic-surgery-forum-2022/csf-2022-highlights/20162/Joel Schlessinger, MD says the 2022 Cosmetic Surgery Forum was a success. The unique format of the meeting encourages presenters and audience members to interact and engage in lively discussions that allow attendees to leave the meeting with ideas they can use in their practices immediately.Lasers and EBDs: Considerations for Ethnic Skin
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/lasers-and-ebds-considerations-for-ethnic-skin/20145/Monica Li, MD reviews evidence-based practices for using lasers, energy-based devices and minimally invasive procedures to manage benign dermatoses to treat patients with skin of color. She discusses the importance of engaging patients in appropriate pre- and post-treatment care to reduce potentialNew Drug Developments in Dermatology
https://practicaldermatology.com/topics/skin-cancer-photoprotection/new-drug-developments-in-dermatology/19971/Despite the COVID pandemic, the FDA had a nearly record year in drug approvals, says Vinod Nambudiri, MD, MBA, which has translated to new developments in dermatology. He discusses approvals of tirbanibulin 1% ointment for actinic keratoses and clascoterone cream 1% for acne, and how they fit into tCOVID-19 Impact: Interrupted EBD Regimens
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/covid-19-impact-on-interrupted-ebd-regimens/19764/Aesthetic treatments aren't considered essential at this time, but what do you do about patients who were in the middle of a series of energy-based treatments? Eric Bernstein, MD says the good news is that the skin doesn't forget. Now is a great time to focus on topical therapies that complement in-Psoriasis Comorbidities: Assessing Risks and the Role of Dermatologists
https://practicaldermatology.com/topics/psoriasis/psoriasis-comorbidities-assessing-risks-and-the-role-of-dermatologists-/18242/Ronald Prussick, MD discusses the most common comorbidities of psoriasis and the risks patients have for cardiovascular issues, depression, fatty liver disease, vitamin D deficiency, and more. He talks to host Nancy Samolitis, MD about the role dermatologists play in assessing and treating these risJuvederm Approved for Lips, CoolMini Applicator Cleared
https://practicaldermatology.com/topics/psoriasis/juvederm-approved-for-lips-coolmini-applicator-cleared/18828/In this edition, a look at Allergan's Juvederm Voluma XC approval for lips an Zeltiq's CoolMini applicator for treatment of the sub mental area. Plus, there's new data for secukinumab in psoriatic arthritis (PSA) and Kathleen Sebelius has joined the Board of Directors of Dermira.The Safety of New Systemics
https://practicaldermatology.com/issues/practicaldermatology-com-march-2025/the-safety-of-new-systemics/33159/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, provides an overview of the safey of systemic therapies such as JAK inhibitors and other similar drugs, giving dermatologists a high-level look at what they need to help clinical decision-making.Practical Dermatology Roundtable: Reclaiming Urticaria, Ch. 5
https://practicaldermatology.com/programs/practical-dermatology/practical-dermatology-roundtable-reclaiming-urticaria-ch-5/85612/In the fifth installment of this five-part series, Brad P. Glick, DO, MPH, FAAD; Laura K. Ferris, MD, PhD; and Lawrence J. Green, MD, FAAD, discuss when to reassess targeted CSU therapies, why prolonged corticosteroid use is problematic, and how dermatologists can take ownership of long-term disease